{"filing":{"accession_number":"0001964738-26-000043","cik":"0001964738","ticker":"SOLV","company_name":"Solventum Corp","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"solv-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1964738/000196473826000043/solv-20260805.htm"},"events":[{"id":25299,"run_id":22956,"accession_number":"0001964738-26-000043","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Solventum announced its intention to pursue a separation of its Health Information Systems business, a $1.4 billion annual revenue segment representing a material portion of the company. The company is evaluating a range of separation alternatives and structures with a target completion within 12-18 months as part of strategic portfolio optimization to transform Solventum into a more dedicated MedTech company.","company_name":"Solventum Corp","ticker":"SOLV","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26086,"accession_number":"0001964738-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Solventum announced its intention to pursue a separation of its Health Information Systems business, a $1.4 billion annual revenue segment representing a material portion of the company. The press release explicitly states the company is \"evaluating a range of separation alternatives and structures\" with a target completion within 12-18 months, and describes this as a strategic portfolio optimization action that will \"transform Solventum into a more dedicated MedTech company.\" This constitutes a material change of control or disposition event under Item 1.01/1.02 framework, even though the ultimate structure remains under evaluation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:26:57.791454+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26087,"accession_number":"0001964738-26-000043","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Solventum announced its intention to pursue a separation of its Health Information Systems business, a $1.4 billion revenue unit, as part of portfolio optimization. The company is evaluating separation pathways with a 12-18 month target completion timeline. This constitutes a material change of control or disposition event—the separation of a major business segment—that would significantly affect the registrant's portfolio composition and shareholder value, fitting the ma_activity category under Items 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:26:57.791454+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26086,"accession_number":"0001964738-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Solventum announced its intention to pursue a separation of its Health Information Systems business, a $1.4 billion annual revenue segment representing a material portion of the company. The press release explicitly states the company is \"evaluating a range of separation alternatives and structures\" with a target completion within 12-18 months, and describes this as a strategic portfolio optimization action that will \"transform Solventum into a more dedicated MedTech company.\" This constitutes a material change of control or disposition event under Item 1.01/1.02 framework, even though the ultimate structure remains under evaluation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:26:57.791454+00:00","company_name":"Solventum Corp","ticker":"SOLV","filing_date":"2026-08-05"},{"id":26087,"accession_number":"0001964738-26-000043","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Solventum announced its intention to pursue a separation of its Health Information Systems business, a $1.4 billion revenue unit, as part of portfolio optimization. The company is evaluating separation pathways with a 12-18 month target completion timeline. This constitutes a material change of control or disposition event—the separation of a major business segment—that would significantly affect the registrant's portfolio composition and shareholder value, fitting the ma_activity category under Items 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:26:57.791454+00:00","company_name":"Solventum Corp","ticker":"SOLV","filing_date":"2026-08-05"}]}